Currently, there are 10.30M common shares owned by the public and among those 10.18M shares have been available to trade.
The company’s stock has a 5-day price change of 117.47% and -71.53% over the past three months. APDN shares are trading -93.65% year to date (YTD), with the 12-month market performance down to -97.39% lower. It has a 12-month low price of $0.31 and touched a high of $30.60 over the same period. APDN has an average intraday trading volume of 1.54 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 99.18%, 79.31%, and -90.33% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Applied Dna Sciences Inc (NASDAQ: APDN) shares accounts for 12.62% of the company’s 10.30M shares outstanding.
It has a market capitalization of $8.06M and a beta (3y monthly) value of 0.08. The earnings-per-share (ttm) stands at -$11.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 43.37% over the week and 17.65% over the month.
Earnings per share for the fiscal year are expected to increase by 67.53%, and 79.03% over the next financial year.
Looking at the support for the APDN, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on February 12, 2021, with the firm’s price target at $24. H.C. Wainwright coverage for the Applied Dna Sciences Inc (APDN) stock in a research note released on January 14, 2021 offered a Buy rating with a price target of $14. H.C. Wainwright was of a view on December 18, 2020 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on July 20, 2020, issuing a price target of $18- $22. H.C. Wainwright on their part issued Buy rating on July 02, 2020.
